Dermatology

If approved, berdazimer could be the first prescription product treat molluscum, a common skin infection caused by poxvirus. The Prescription Drug User Fee Act goal date is Jan. 5, 2024.

Cibinqo is an oral, once-daily JAK1 inhibitor now approved for those 12 years of age and older.

In this Managed Healthcare Executive® K-Cast, David Rosmarin, M.D., vice chair of education and research in the Department of Dermatology at Tufts Medical Center in Boston, discussed the economic burden, treatment goals, treatment options and health insurance issues related to vitiligo.

Because vitiligo affects appearance, people with vitiligo are disproportionately affected by psychiatric conditions, including depression.

The melanocytes attacked by the autoimmune disease are present in the eyes and ears, not just the skin, so vitiligo can adversely affect vision and hearing.

Formulary placement is crucial to the commercial success of newly approved products, so Acrutis put out a press release last week announcing that Express Scripts had put Zoryve (roflumilast), the company's PDE4 inhibitor cream for plaque psoriasis, on its formulary.

Israeli researchers find more than a fivefold risk of developing systemic sclerosis among people with vitiligo.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Taking 80 mg of the high-cholesterol statin drug daily can control patients' vitiligo activity and protect them against the hazardous effects of dyslipidemia.

Launched in August, Zoryve is a once-daily, steroid-free cream and is the first topical PDE4 inhibitor approved to treat plaque psoriasis in patients 12 years of age or older.

Dupixent is the first treatment approved to treat prurigo nodularis, a chronic skin disorder characterized by the presence of hard, itchy nodules.

The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.

While phototherapy has been shown to have a positive effect on vitiligo as it works to reduce or prevent the destruction of skin cells, treatment done in the hospital can be long-term and require a number of visits.

Commercial shipments are already under way of Cosette’s gel formulation of tazarotene to treat patients with acne and facial wrinkles.

Developed by Bristol Myers Squibb, Sotyktu is the first approved TYK2 inhibitor. It is expected to be available later this month.

The FDA is expected to make a decision on Pfizer’s ritlecitinib in the second quarter of 2023.

Daxxify enters the injectable botulinum toxin market as a twice-a year treatment for frown lines.

Spevigo is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling approved to treat for adults with generalized pustular psoriasis flares.

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

Laser treatment presents as being highly effective for vitiligo repigmentation over other forms of treatment.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

Zoryve is a next-generation topical PDE4 inhibitor to treat adults and adolescents with plaque psoriasis.

Zoryve, the first topical PDE4 inhibitor approved to treat patients with plaque psoriasis, will be available by mid-August.

Opzelura is first therapy approved to treat patients with vitiligo, a disease that causes the loss of skin color.

Piclidenoson is a first-in-class, A3 adenosine receptor agonist small molecule that inhibits the inflammatory cytokines interleukin 17 and 23.

Olumiant is the first systemic therapy available to treat alopecia.

Dupixent is the first biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.

If approved, Dupixent would be the first and only medicine in the United States specifically indicated to treat prurigo nodularis, or persistent itch with thick skin lesions. The PDUFA target action date for the FDA decision is Sept. 30, 2022.

Deficiencies at the contract manufacturing company are, for the second time, holding up approval of VP-102 to treat molluscum contagiosum, a mild skin infection.